Steris (STE) Q1 Revenue Rises 8%

Steris (NYSE:STE) reported Q1 FY2026 results where both GAAP revenue and non-GAAP EPS missed analyst estimates, despite robust year-over-year growth and strong segment performance. The company subsequently raised its full-year FY2026 reported revenue growth outlook to 8-9% due to favorable foreign currency. However, adjusted EPS guidance for FY2026 was held flat, as increasing tariffs—now projected to impact pre-tax profit by $45 million—and rising employee costs are expected to fully offset the incremental revenue gains, signaling persistent cost pressures despite solid operational execution and recurring revenue growth.

Analysis

Steris (STE) reported a mixed Q1 FY2026, missing analyst consensus on both GAAP revenue and non-GAAP EPS. Revenue came in at $1,391.1 million against an estimate of $1,447.8 million, while adjusted EPS was $2.34 versus an expected $2.47. Despite the misses, the company demonstrated robust underlying operational strength, with year-over-year revenue growth of 8.7% and a 15.3% increase in non-GAAP EPS, fueled by solid performance across all segments. Particularly strong were recurring revenue streams, with Healthcare services up 13% and Applied Sterilization Technologies (AST) services growing 12.6%. However, the key takeaway is the pressure on profitability. Management raised its full-year FY2026 revenue growth forecast from 6-7% to 8-9%, but this was attributed entirely to favorable foreign currency exchange rates. Critically, the adjusted EPS guidance was held flat, as the benefits from the higher revenue outlook are expected to be completely negated by escalating costs. Specifically, the projected pre-tax profit impact from tariffs has increased by 50% from $30 million to $45 million, and this, combined with rising employee benefit expenses, is compressing margins despite strong cash flow generation and healthy demand indicated by a 53.8% Y/Y increase in the Life Sciences backlog.

Key Decisions for Investors

• Investors should weigh the company's strong operational execution, evident in double-digit recurring service revenue growth and robust cash flow, against the significant margin pressure from rising tariffs and labor costs which neutralized FX tailwinds.
• It is crucial to monitor developments in U.S. trade policy and employee cost inflation, as these external factors are the primary risks to the unchanged EPS guidance and the company's profitability outlook.
• Re-evaluate valuation models to account for the heightened cost structure, particularly the incremental $15 million in expected tariff impact, as this directly compresses the profitability outlook despite the upward revision in revenue guidance.
• Focus on the company's ability to meet its raised non-GAAP free cash flow guidance of $820 million as a key positive indicator that could support shareholder returns and buffer against the near-term earnings squeeze.